The World Health Organization (WHO) has prequalified the thermostable rotavirus vaccine, Rotasil® manufactured by Serum Institute of India.
The vaccine, which prevents severe rotavirus-induced diarrhea in infants, provides an innovative and affordable option to the global market as it is the first rotavirus vaccine that does not require constant refrigeration and will help meet the critical public health goal of improving vaccine supply worldwide. The vaccine will now be available for procurement by United Nations agencies and Gavi, the Vaccine Alliance for use in low- and middle-income countries. This will help accelerate availability of the vaccine in coun-tries experiencing the highest burden of rotavirus-induced diarrhea by providing a practical and affordable option for vaccine introduction.
Rotavirus is the most common cause of severe diarrheal disease in children worldwide, and vaccination is the best way to prevent severe rotavirus illness.
To view the current issue of the Global Immunization Newsletter visit the WHO Global Immunization Newsletters webpage: www.who.int/immunization/gin.